239 related articles for article (PubMed ID: 33266377)
41. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.
Reed E
Cancer Treat Rev; 1998 Oct; 24(5):331-44. PubMed ID: 9861196
[TBL] [Abstract][Full Text] [Related]
42. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
[TBL] [Abstract][Full Text] [Related]
43. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
De Silva IU; McHugh PJ; Clingen PH; Hartley JA
Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
[TBL] [Abstract][Full Text] [Related]
44. [Importance of expression of DNA repair proteins in non-small-cell lung cancer].
Rybárová S; Muri J; Hodorová I; Vecanová J; Benický M; Piovarči D; Janík P; Mihalik J; Mirossay L
Klin Onkol; 2012; 25(5):370-4. PubMed ID: 23102199
[TBL] [Abstract][Full Text] [Related]
45. Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?
Bergstralh DT; Sekelsky J
Trends Genet; 2008 Feb; 24(2):70-6. PubMed ID: 18192062
[TBL] [Abstract][Full Text] [Related]
46. MZF1 possesses a repressively regulatory function in ERCC1 expression.
Yan QW; Reed E; Zhong XS; Thornton K; Guo Y; Yu JJ
Biochem Pharmacol; 2006 Mar; 71(6):761-71. PubMed ID: 16426580
[TBL] [Abstract][Full Text] [Related]
47. The place of excision repair cross complementation 1 (ERCC1) in surgically treated non-small cell lung cancer.
Breen D; Barlési F
Eur J Cardiothorac Surg; 2008 May; 33(5):805-11. PubMed ID: 18342529
[TBL] [Abstract][Full Text] [Related]
48. ERCC1: impact in multimodality treatment of upper gastrointestinal cancer.
Metzger R; Bollschweiler E; Hölscher AH; Warnecke-Eberz U
Future Oncol; 2010 Nov; 6(11):1735-49. PubMed ID: 21142660
[TBL] [Abstract][Full Text] [Related]
49. [ERCC1 as a Marker of Ovarian Cancer Resistance to Platinum Drugs].
Bogush TA; Popova AS; Dudko EA; Bogush EA; Tyulyandina AS; Tyulyandin SA; Davydov MI
Antibiot Khimioter; 2015; 60(3-4):42-50. PubMed ID: 26415382
[TBL] [Abstract][Full Text] [Related]
50. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.
Lv Y; Xu M; Sun Y; Liu Y; Zhao L; Liu X; Li Z; Shi G; Jia J; Bi L; Ma N; Zhang X; Qi C
Medicine (Baltimore); 2021 Aug; 100(33):e26850. PubMed ID: 34414935
[TBL] [Abstract][Full Text] [Related]
51. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
Fujii T; Toyooka S; Ichimura K; Fujiwara Y; Hotta K; Soh J; Suehisa H; Kobayashi N; Aoe M; Yoshino T; Kiura K; Date H
Lung Cancer; 2008 Mar; 59(3):377-84. PubMed ID: 17905465
[TBL] [Abstract][Full Text] [Related]
52. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
53. ERCC1 single nucleotide polymorphism C8092A, but not its expression is associated with survival of esophageal squamous cell carcinoma patients from Fujian province, China.
Chen WH; Xin PL; Pan QX; Chen YY; Wang CR; Zhang ZS; Chen YF; Zhang CY; Cai WJ
PLoS One; 2014; 9(9):e106600. PubMed ID: 25191856
[TBL] [Abstract][Full Text] [Related]
54. The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways.
Orelli B; McClendon TB; Tsodikov OV; Ellenberger T; Niedernhofer LJ; Schärer OD
J Biol Chem; 2010 Feb; 285(6):3705-3712. PubMed ID: 19940136
[TBL] [Abstract][Full Text] [Related]
55. Nucleotide excision repair pathways involved in Cisplatin resistance in non-small-cell lung cancer.
Rosell R; Taron M; Barnadas A; Scagliotti G; Sarries C; Roig B
Cancer Control; 2003; 10(4):297-305. PubMed ID: 12915808
[TBL] [Abstract][Full Text] [Related]
56. Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Tian C; Muggia F; Dhir R; Armstrong DK; Bookman MA; Niedernhofer LJ; Deloia J; Birrer M; Krivak TC
Gynecol Oncol; 2012 May; 125(2):421-6. PubMed ID: 22261301
[TBL] [Abstract][Full Text] [Related]
57. Immunohistochemical expression of excision repair cross-complementing 1 (ERCC1) in non-small-cell lung cancer: implications for patient outcome.
Cubukcu E; Fatih Olmez O; Saraydaroglu O; Akcali U; Kanat O; Kurt E; Evrensel T; Manavoglu O
Clin Transl Oncol; 2011 Nov; 13(11):826-30. PubMed ID: 22082649
[TBL] [Abstract][Full Text] [Related]
58. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
[TBL] [Abstract][Full Text] [Related]
59. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
[TBL] [Abstract][Full Text] [Related]
60. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.
Ota S; Ishii G; Goto K; Kubota K; Kim YH; Kojika M; Murata Y; Yamazaki M; Nishiwaki Y; Eguchi K; Ochiai A
Lung Cancer; 2009 Apr; 64(1):98-104. PubMed ID: 18823676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
